The Role of Imaging in the Diagnosis of Acute Appendicitis During the COVID-19 Pandemic
The Role of Imaging in the Diagnosis of Acute Appendicitis During the COVID-19 Pandemic: a Retrospective Cohort Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, NW1 2BU
- University College London Hospitals NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients of all ages who underwent emergency appendicectomy (either laparoscopic or open) for suspected acute appendicitis
- Patients of all ages who underwent partial ileo-caecectomy or right hemicolectomy for suspected acute appendicitis
Exclusion Criteria:
- Patients who underwent elective interval appendicectomy for a previous appendiceal phlegmon
- Patients who underwent appendicectomy or right hemicolectomy for appendiceal tumours
- Patients who underwent diagnostic laparoscopy for suspected acute appendicitis, where the appendix was not removed
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Pandemic Group
All patients who underwent emergency appendicectomy for suspected acute appendicitis between March 2020 and February 2021
|
Use of pre-operative imaging or the diagnosis of acute appendicitis
|
|
Control Group
All patients who underwent emergency appendicectomy for suspected acute appendicitis between March 2019 and February 2020
|
Use of pre-operative imaging or the diagnosis of acute appendicitis
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Negative Appendicectomy Rate (NAR)
Time Frame: Up to 3 weeks post-operatively (when final Histology is ready)
|
Number of patients with final histology negative for acute appendicitis
|
Up to 3 weeks post-operatively (when final Histology is ready)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-Operative Length of Stay
Time Frame: Assessed on day 30 after the completion of the study
|
Post-operative length of hospital stay (from post-operative day 1)
|
Assessed on day 30 after the completion of the study
|
|
Post-Operative Complications Rate
Time Frame: Within 30 post-operative days
|
Number of patients who had post-operative complications
|
Within 30 post-operative days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Gerardo Perrotta, MD, University College London Hospitals
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Intestinal Diseases
- Cecal Diseases
- Intraabdominal Infections
- COVID-19
- Appendicitis
Other Study ID Numbers
Other Study ID Numbers
- NARCO2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.